Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy

被引:162
|
作者
Porter, GA [1 ]
Pisters, PWT [1 ]
Mansyur, C [1 ]
Bisanz, A [1 ]
Reyna, K [1 ]
Stanford, P [1 ]
Lee, JE [1 ]
Evans, DB [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
pancreaticoduodenectomy; costs; clinical pathway; resource utilization;
D O I
10.1007/s10434-000-0484-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:When implemented in several common surgical procedures, clinical pathways have been reported to reduce costs and resource utilization, while maintaining or improving patient care. However, then is little data to support their use in more complex surgery. The objective of this study was to determine the effects of clinical pathway implementation in patients undergoing elective pancreaticoduodenectomy (PD) on cost and resource utilization. Methods: Outcome data from before and after the development of a clinical pathway were analyzed. The clinical pathway standardized the preoperative outpatient care, critical care, and postoperative floor care of patients who underwent PD. An independent department determined total costs for each patient, which included all hospital and physician costs, in a blinded review. Outcomes that were examined included perioperative mortality, postoperative morbidity, length of stay, readmissions, and postoperative clinic visits. Results: From January, 1996 to December, 1998, 148 consecutive patients underwent PD or total pancreatectomy; 68 before pathway development (PrePath) and 80 after pathway implementation (PostPath). There were no significant differences in patient demographics, comorbid conditions, underlying diagnosis, or use of neoadjuvant therapy between the two groups. Mean total costs were significantly reduced in PostPath patients compared with PrePath patients ($36,627 vs. $47,515; P = .003). Similarly, mean length of hospital stay was also significantly reduced in PostPath patients (13.5 vs. 16.4 days; P = .001). The total cost differences could not be attributed solely to differences in room and board costs. Cost and length-of-stay differences remained when outliers were excluded from the analysis. Despite these findings, there were no significant differences between PrePath and PostPath patients in terms of perioperative mortality (3% vs, 1%), readmissions within 1 month of discharge (15% vs. 11%), or mean number of clinic visits within 90 days of discharge (3.3 vs. 3.3 visits). Conclusions: The establishment of a clinical pathway for PD patients dramatically reduced costs and resource utilization without any apparent detrimental effect on quality of patient care. These findings support the implementation of clinical pathways for PD patients, as well as investigation into pathway care for other complex surgical procedures.
引用
收藏
页码:484 / 489
页数:6
相关论文
共 50 条
  • [21] Impact of Coronary Artery Stenting on Perioperative Mortality and Complications in Patients Undergoing Pancreaticoduodenectomy
    Thuy Tran
    Maker, Vijay K.
    Maker, Ajay V.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : S172 - S173
  • [22] The Role of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
    Jablonska, Beata
    Mrowiec, Slawomir
    NUTRIENTS, 2020, 12 (09) : 1 - 15
  • [23] The impact of preoperative renal insufficiency on the outcomes of patients with pancreatic cancer undergoing pancreaticoduodenectomy
    Tamura, Shunsuke
    Kanemoto, Hideyuki
    Fujita, Akitsugu
    Tokuda, Satoshi
    Takagi, Akihiko
    Nakatani, Eiji
    Taku, Keisei
    Oba, Noriyuki
    LANGENBECKS ARCHIVES OF SURGERY, 2024, 409 (01)
  • [24] Impact of Postoperative Glycemic Control on Postoperative Morbidity in Patients Undergoing Open Pancreaticoduodenectomy
    Yun, Regina
    Javed, Ammar A.
    Jarrell, Andrew S.
    Crow, Jessica
    Wright, Michael J.
    Burkhart, Richard A.
    Rybny, Joseph
    Wolfgang, Christopher L.
    Kruer, Rachel M.
    PANCREAS, 2021, 50 (06) : 834 - 840
  • [25] Clinical and Pathologic Features Influencing Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma
    Cynthia E. Weber
    Eileen A. Bock
    Michael G. Hurtuk
    Gerard J. Abood
    Jack Pickleman
    Margo Shoup
    Gerard V. Aranha
    Journal of Gastrointestinal Surgery, 2014, 18 : 340 - 347
  • [26] Clinical and Pathologic Features Influencing Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma
    Weber, Cynthia E.
    Bock, Eileen A.
    Hurtuk, Michael G.
    Abood, Gerard J.
    Pickleman, Jack
    Shoup, Margo
    Aranha, Gerard V.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (02) : 340 - 347
  • [27] Surgeon Volume Versus Morbidity and Cost in Patients Undergoing Pancreaticoduodenectomy in an Academic Community Medical Center
    Timothy J. Kennedy
    Maria A. Cassera
    Ronald Wolf
    Lee L. Swanstrom
    Paul D. Hansen
    Journal of Gastrointestinal Surgery, 2010, 14 : 1990 - 1996
  • [28] Association between oncology clinical pathway utilization and quality and cost outcomes in patients with metastatic solid tumors
    Liu, Ying
    Mullangi, Samyukta
    Chen, Xiaoxue
    Pham, Timothy
    Debono, David Joseph
    Fisch, Michael Jordan
    Gordon, Aliza
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 430 - 430
  • [29] Surgeon Volume Versus Morbidity and Cost in Patients Undergoing Pancreaticoduodenectomy in an Academic Community Medical Center
    Kennedy, Timothy J.
    Cassera, Maria A.
    Wolf, Ronald
    Swanstrom, Lee L.
    Hansen, Paul D.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2010, 14 (12) : 1990 - 1996
  • [30] Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors
    Liu, Ying
    Mullangi, Samyukta
    Debono, David
    Chen, Xiaoxue
    Pham, Timothy
    Fisch, Michael J.
    Gordon, Aliza S.
    Hershman, Dawn L.
    JCO ONCOLOGY PRACTICE, 2023, 19 (09) : 731 - +